Addressing major obstacles in the development and manufacturing of CGTs with Jon Ellis, CEO of Trenchant BioSystems. As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated CGT manufacturing
Supplier News: Fujifilm Irvine Scientific, Pace Life Sciences Company — Trenchant Biosystems Philip H. Coelho, currently serving as Chairman and CTO of Trenchant BioSystems, Inc. is an engineer/ inventor, educated at the University of California, Davis.
Trenchant, Inc. As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into its automated manufacturing
Trenchant & Autolomous Partner to Accelerate Cell & Gene Therapy Philip Coelho - Chairman & CTO of Trenchant BioSystems, Inc The new industry deals progressing drug discovery - Drug Discovery
sunrise video Cells video 1
Trenchant Biosystems specializes in developing scalable and efficient cell therapy manufacturing technologies that streamline processes, Trenchant Bio is making cell and gene therapies (CGT) more affordable and accessible to patients. We were founded in 2022 to create cell therapy manufacturing
As a result of the partnership, Trenchant BioSystems will integrate Autolomous' autoloMATE digital solution into their automated CGT Trenchant Biosystems Under the partnership, the companies will combine fully automated and digitalized technologies aimed at reducing CGT manufacturing timelines
Trenchant BioSystems, tells GEN. CGT-in-a-box. To address those issues, Trenchant is developing a fully-automated cell therapy manufacturing Private equity investments demand strategic growth, operational excellence, and measurable outcomes. At Trenchant, we specialize in helping businesses achieve
Trenchant BioSystems and Autolomous to Combine Platforms for Cell and Gene Therapy Manufacturing Challenges & Solutions Cancer cells video 1
Fully-Automated CAR-T Bioprocessing Platform Aids Scalability